Pharmacological modulation of ATP-sensitive potassium channels has become a promising new therapeutic approach for the treatment of neurodegenerative diseases due to their role in mitochondrial and cellular protection. For instance, diazoxide, a well-known ATP-sensitive potassium channel activator with high affinity for mitochondrial component of the channel has been proved to be effective in animal models for different diseases such as Alzheimer’s disease, stroke or multiple sclerosis. Here, we analyzed the ability of diazoxide for protecting neurons front different neurotoxic insults in vitro and ex vivo. Results showed that diazoxide effectively protects NSC-34 motoneurons from glutamatergic, oxidative and inflammatory damage. Moreover, ...
Chronic cerebral hypoperfusion, a mild ischemic condition is associated with advancing age and sever...
Background and Purpose - Mitochondrial ATP-sensitive potassium (mitoKATP) channels are present in th...
Objective: Even today there is no effective drug therapy to prevent neuronal loss after brain stroke...
Diazoxide, a well-known mitochondrial KATP channel opener with neuroprotective effects, has been pro...
Abstract Background Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of th...
Background Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of the central...
<p>Western blot showed an increase of Nrf2 signaling in the nuclear extracts from NSC-34 neurons tre...
Several clinical conditions are associated with white matter injury, including periventricular white...
<p>Representative images of differentiated NSC-34 motoneuron cells line after glutamate damage and d...
Diazoxide is a putative mitochondrial, ATP-sensitive potassium channel opener that has been implicat...
Activation of mitochondrial ATP-sensitive potassium (KATP) channels is postulated as an effective me...
Objective. We investigated whether and how diazoxide can attenuate brain injury after cardiopulmonar...
Diazoxide has been identified as a mitochondrial, ATP-dependent K+ channel opener, and a potentially...
Diazoxide (DIAZ), an opener of mitochondrial ATP-sensitive K+ channels (mK(ATP)), protects neurons a...
A B S T R A C T Introduction: Even today there is no effective drug therapy to prevent neuronal loss...
Chronic cerebral hypoperfusion, a mild ischemic condition is associated with advancing age and sever...
Background and Purpose - Mitochondrial ATP-sensitive potassium (mitoKATP) channels are present in th...
Objective: Even today there is no effective drug therapy to prevent neuronal loss after brain stroke...
Diazoxide, a well-known mitochondrial KATP channel opener with neuroprotective effects, has been pro...
Abstract Background Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of th...
Background Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disorder of the central...
<p>Western blot showed an increase of Nrf2 signaling in the nuclear extracts from NSC-34 neurons tre...
Several clinical conditions are associated with white matter injury, including periventricular white...
<p>Representative images of differentiated NSC-34 motoneuron cells line after glutamate damage and d...
Diazoxide is a putative mitochondrial, ATP-sensitive potassium channel opener that has been implicat...
Activation of mitochondrial ATP-sensitive potassium (KATP) channels is postulated as an effective me...
Objective. We investigated whether and how diazoxide can attenuate brain injury after cardiopulmonar...
Diazoxide has been identified as a mitochondrial, ATP-dependent K+ channel opener, and a potentially...
Diazoxide (DIAZ), an opener of mitochondrial ATP-sensitive K+ channels (mK(ATP)), protects neurons a...
A B S T R A C T Introduction: Even today there is no effective drug therapy to prevent neuronal loss...
Chronic cerebral hypoperfusion, a mild ischemic condition is associated with advancing age and sever...
Background and Purpose - Mitochondrial ATP-sensitive potassium (mitoKATP) channels are present in th...
Objective: Even today there is no effective drug therapy to prevent neuronal loss after brain stroke...